In vivo antispasmodic activity of Sulcotidil.
Suloctidil was tested in vivo for its antispasmodic activity on peripheral and cerebral circulations. In the perfused dog hind limb preperation, suloctidil was found to inhibit after 2 and 5 min, the vasospasm induced by norepinephrine or angiotensin; at equal dose, and at the game time intervals, it was more potent than cinnarizine and papaverine. BaCl(2) induced spasms of the pial arterial of the rabbit were also rapidly alleviated by i.a. suloctidil (3.5 mug/kg or more), in conditions where papaverine and vincamine were inactive.
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002936:Cinnarizine / Q000494:pharmacology; D004285:Dogs; D005260:Female; D006614:Hindlimb / Q000098:blood supply; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010208:Papaverine / Q000494:pharmacology; D010276:Parasympatholytics; D011412:Propanolamines / Q000494:pharmacology*; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D014748:Vinca Alkaloids / Q000494:pharmacology
D010276:Parasympatholytics; D011412:Propanolamines; D014748:Vinca Alkaloids; D000804:Angiotensin II; D002936:Cinnarizine; D010208:Papaverine; D009638:Norepinephrine